Cure My Disease

Don't miss your cure!

 Log in / Sign up

Precision radiation boost may curb rare Cancer's return

NCT ID NCT01841047

Completed Disease control Sponsor: Institut Bergonié Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether giving a higher dose (54 Gy) of a very precise type of radiation called helical tomotherapy before surgery could improve outcomes for people with retroperitoneal liposarcoma, a rare cancer in the abdomen. The 48 participants received the radiation and then had surgery. The main goal was to see how many people remained free of local recurrence three years later. The results help understand if this more intense radiation approach is worth further study.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
helical tomotherapy radiotherapy (54 Gy)
What this could lead to
If successful, this approach could offer a way to reduce local recurrence of retroperitoneal liposarcoma after surgery.
What could go wrong
This was a small, early-phase study (48 participants) with no control group, so results may not be generalizable. The higher radiation dose also carries increased risk of organ toxicity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIPOSARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

liposarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LIPOSARCOMA

Contacts and locations

Locations

  • Centre Claudius Regaud

    Toulouse, Midi-Pyrénées, 31000, France

  • Centre Paul Strauss

    Strasbourg, Alsace, 67000, France

  • Centre René Gauducheau

    Nantes, Pays de la Loire Region, 44000, France

  • Institut Bergonié

    Bordeaux, Aquitaine, 33000, France

  • Institut Curie

    Paris, Île-de-France Region, 75000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.